晚期前列腺癌治疗期间肿瘤消退与生长速率的估算:一项回顾性分析
本回顾性分析利用Project Data Sphere共享的8项随机临床试验数据,对转移性去势抵抗性前列腺癌患者应用数学模型,以前列腺特异性抗原水平代表肿瘤负荷,估算疾病负荷的生长速率(g)与消退速率(d)。g可区分多西他赛与泼尼松及米托蒽醌,并在8个月界标分析中预测总生存;以g为终点的模拟样本量分析显示较小样本即可达到80%把握度。停用多西他赛后中位肿瘤生长速率增加近五倍。
要点
- 在2678例可分析患者中,2353例(88%)获得g、d或两者估计值。
- g可区分多西他赛与泼尼松及米托蒽醌,并在8个月界标分析中预测总生存。
- 停用多西他赛后中位肿瘤生长速率增加近五倍。
核心结论
- 对现有临床数据应用数学模型可估算生长与消退速率,为转移性去势抵抗性前列腺癌提供新见解。
- 通过Project Data Sphere等倡议获取临床数据并结合创新建模技术,可加深对癌症治疗反应的理解并加速临床开发效率。
研究设计与样本
- 本回顾性分析使用Project Data Sphere LLC(美国北卡罗来纳州卡里)共享的8项随机临床试验数据,这些试验入组转移性去势抵抗性前列腺癌患者。
- 以前列腺特异性抗原水平代表肿瘤量,应用数学模型估算疾病负荷随时间的生长速率(g)与消退速率(d)。
- 比较研究干预(泼尼松、米托蒽醌和多西他赛)之间以及停药后的速率,以理解治疗期间和停药后的疾病行为。
- 检验g与总生存这一传统终点的关联,并评估其作为减少临床试验样本量终点的潜力。
主要发现
- 在2678例有可分析数据的患者中,2353例(88%)获得g、d或两者估计值。
- g可区分多西他赛(美国食品药品监督管理局批准疗法)与泼尼松及米托蒽醌,并在8个月界标分析中预测总生存。
- 以g为终点的模拟样本量分析比较多西他赛与米托蒽醌数据,显示三个多西他赛对照组的样本量分别为16、47和25例时足以达到80%把握度。
- 米托蒽醌数据与泼尼松数据比较时结果相似,三个米托蒽醌对照组的样本量分别为41、39和41例。
- 停用多西他赛治疗后,中位肿瘤生长速率(g)增加近五倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We applied mathematical models to clinical trial data available at Project Data Sphere LLC (Cary, NC, USA), a non-profit universal access data-sharing warehouse. Our aim was to assess the rates of cancer growth and regression using the comparator groups of eight randomised clinical trials that enrolled patients with metastatic castration-resistant prostate cancer. METHODS: In this retrospective analysis, we used data from eight randomised clinical trials with metastatic castration-resistant prostate cancer to estimate the growth (g) and regression (d) rates of disease burden over time. Rates were obtained by applying mathematical models to prostate-specific antigen levels as the representation of tumour quantity. Rates were compared between study interventions (prednisone, mitoxantrone, and docetaxel) and off-treatment data when on-study treatment had been discontinued to understand disease behaviour during treatment and after discontinuation. Growth (g) was examined for association with a traditional endpoint (overall survival) and for its potential use as an endpoint to reduce sample size in clinical trials. FINDINGS: Estimates for g, d, or both were obtained in 2353 (88%) of 2678 patients with data available for analysis; g differentiated docetaxel (a US Food and Drug Administration-approved therapy) from prednisone and mitoxantrone and was predictive of overall survival in a landmark analysis at 8 months. A simulated sample size analysis, in which g was used as the endpoint, compared docetaxel data with mitoxantrone data and showed that small sample sizes were sufficient to achieve 80% power (16, 47, and 25 patients, respectively, in the three docetaxel comparator groups). Similar results were found when the mitoxantrone data were compared with the prednisone data (41, 39, and 41 patients in the three mitoxantrone comparator groups). Finally, after discontinuation of docetaxel therapy, median tumour growth (g) increased by nearly five times. INTERPRETATION: The application of mathematical models to existing clinical data allowed estimation of rates of growth and regression that provided new insights in metastatic castration-resistant prostate cancer. The availability of clinical data through initiatives such as Project Data Sphere, when combined with innovative modelling techniques, could greatly enhance our understanding of how cancer responds to treatment, and accelerate the productivity of clinical development programmes. FUNDING: None.
引用
- Wilkerson J, Abdallah K, Hugh-Jones C, et al. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncol. 2016. PMID: 27979599. doi:10.1016/S1470-2045(16)30633-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。